Evidence map›Paper›PMID 28633629›Full record

ArticleBMC neurology2017

Prevalence of and risk factors for severe cognitive and sleep symptoms in ME/CFS and MS.

Vageesh Jain, Amit Arunkumar, Caroline Kingdon, Eliana Lacerda, Luis Nacul

Abstract read
In one paragraph

Article in BMC neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vageesh JainGuy's Campus, King's College London School of Medicine, London, SE1 1UL, UK. vageesh.jain@kcl.ac.uk.
Amit ArunkumarUniversity of California, San Francisco, School of Medicine, San Francisco, CA, 94143, USA.
Caroline KingdonFaculty of Infectious and Tropical Diseases, CURE-ME Team, London School of Hygiene & Tropical Medicine Disability and Eye Health Group, International Centre for Evidence in Disability (ICED, K/490, Keppel St, London, WC1E 7HT, UK.
Eliana LacerdaFaculty of Infectious and Tropical Diseases, CURE-ME Team, London School of Hygiene & Tropical Medicine Disability and Eye Health Group, International Centre for Evidence in Disability (ICED, K/490, Keppel St, London, WC1E 7HT, UK.
Luis NaculFaculty of Infectious and Tropical Diseases, CURE-ME Team, London School of Hygiene & Tropical Medicine Disability and Eye Health Group, International Centre for Evidence in Disability (ICED, K/490, Keppel St, London, WC1E 7HT, UK.

Funding

A longitudinal immunological and virological study for ME CFS biomarker discovery (Renewal)R01AI103629 · NIAID · LONDON SCH/HYGIENE & TROPICAL MEDICINE · PI DOCKRELL, HAZEL MARGUERITE, NACUL, LUIS · 2013 to 2020
$4.1M
Medical Research Council MC_QA137853NIAID NIH HHS R01 AI103629
6 · The paper itself

Abstract

backgroundThere are considerable phenotypic and neuroimmune overlaps between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and multiple sclerosis (MS). While the precise aetiologies of both MS and ME/CFS are unclear, evidence suggests that deterioration in cognitive function is widely prevalent in patients with either condition. Little is known about differing risk factors or exposures, which may lead to severe cognitive or sleep symptoms. This study aims to gauge the extent of cognitive and sleep symptoms in ME/CFS and MS patients participating in the UK ME/CFS Biobank and identify the characteristics of those experiencing severe symptoms.

methodsThis was a cross-sectional study of 395 UK ME/CFS Biobank participants, recruited from primary care and the community, using similar standardised protocols, and matched by age, sex and geographical area. Data were collected from participants using a standardized written questionnaire at clinical visits. Cognitive symptoms included problems with short-term memory, attention, and executive function. Sleep symptoms included unrefreshing sleep and poor quality or inadequate duration of sleep. All participants reported symptoms based on an ordinal severity scale. Multivariable logistic regression was carried out in the ME/CFS group to investigate socio-demographic factors associated with severe symptoms.

resultsAll cognitive and sleep symptoms were more prevalent in the ME/CFS group, with 'trouble concentrating' (98.3%) the most commonly reported symptom. Severe symptoms were also more commonly reported in the ME/CFS group, with 55% reporting 'severe, unrefreshing sleep'. Similarly, in the MS group, the most commonly reported severe symptoms were sleep-related. Logistic regression analysis revealed that ME/CFS patients aged over 50 years were more than three times as likely to experience severe symptoms than those younger than 30 (OR 3.23, p = 0.031). Current smoking was associated with severe symptoms, increasing the risk by approximately three times (OR 2.93, p = 0.003) and those with household incomes of more than £15,000 per year were less likely to experience severe symptoms compared to those earning less than this (OR 0.31, p = 0.017).

conclusionsCognitive and sleep symptoms are more common in ME/CFS patients than in MS patients and healthy controls, providing further support for existing evidence of central nervous system abnormalities in ME/CFS. Our findings suggest that people with ME/CFS who are smokers, or have a low income, are more likely to report severe cognitive and sleep symptoms. Future research should aim to develop strategies to prevent the progression of severe cognitive and sleep symptoms through early interventions that prioritise patients identified as being at highest risk.

Indexed as

CognitionSleepAdultCase-Control StudiesCross-Sectional StudiesFatigue Syndrome, ChronicFemaleHumansLogistic ModelsMaleMemory, Short-TermMiddle AgedMultiple SclerosisPrevalencePrimary Health CareRisk FactorsCognitive symptomsME/CFSMSRisk factorsSeveritySleep

Identifiers

PMID28633629
PMCPMC5477754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.